5.42
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Why analysts upgrade Candel Therapeutics Inc. stockPortfolio Performance Summary & Short-Term Swing Trade Alerts - newser.com
Comparing Candel Therapeutics Inc. in custom built stock radarsProduct Launch & Verified Momentum Stock Alerts - newser.com
How resilient is Candel Therapeutics Inc. stock in market downturnsDollar Strength & Safe Capital Growth Trade Ideas - newser.com
Will Candel Therapeutics Inc. stock reach all time highs in 2025July 2025 Spike Watch & Precise Swing Trade Entry Alerts - newser.com
Reversal indicators forming on Candel Therapeutics Inc. stock2025 Macro Impact & Low Risk Entry Point Tips - newser.com
Candel Therapeutics announces interim data from phase 1b CAN-3110 trial - Yahoo Finance
Candel Therapeutics Funding Could Be A Game Changer For Trinity Capital (TRIN) - simplywall.st
Candel Thera secures $130 million loan facility with Trinity Capital - The Pharma Letter
Candel Therapeutics secures $130M loan facility to advance clinical pipeline - Proactive financial news
Small cap wrap: Millennial Potash, Nextech3D.ai, Candel Therapeutics, Charbone Hydrogen... - Proactive financial news
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc - MarketScreener
Candel Therapeutics Secures $130M Loan for Trials - TipRanks
Candel Therapeutics secures $130M loan to advance cancer therapy trials - Proactive financial news
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - The AI Journal
Candel Therapeutics secures $130 million term loan facility - Investing.com
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - The Manila Times
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine - The Manila Times
Candel Therapeutics Incannounces encouraging interim data from CAN-3110 trial - MarketScreener
Candel Therapeutics Reports Promising Interim Data for CAN-3110 in Recurrent Glioblastoma and Publication in Science Translational Medicine - Quiver Quantitative
Candel Therapeutics Announces Positive Interim Data After - GlobeNewswire
Candel Therapeutics Reports CAN-3110 Pathologic CR, mOS 12.0 mo | CADL Stock News - Stock Titan
Can Candel Therapeutics Inc. stock sustain revenue growthMarket Sentiment Summary & Daily Chart Pattern Signal Reports - newser.com
Candel Therapeutics Inc. stock retracement – recovery analysisEntry Point & High Accuracy Swing Trade Signals - newser.com
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha
Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer - Stocktwits
Will Candel Therapeutics Inc. stock deliver strong dividend growth2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
What MACD signals say about Candel Therapeutics Inc.Market Risk Report & Real-Time Volume Analysis - newser.com
Analyzing drawdowns of Candel Therapeutics Inc. with statistical tools2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
How to interpret RSI for Candel Therapeutics Inc. stockWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Is Candel Therapeutics Inc a good long term investmentProtective Put Strategies & Outstanding Wealth Building - earlytimes.in
Visual trend scoring systems applied to Candel Therapeutics Inc.July 2025 Price Swings & High Win Rate Trade Tips - newser.com
Price momentum metrics for Candel Therapeutics Inc. explainedWeekly Trading Summary & Community Verified Trade Signals - newser.com
Candel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Is Candel Therapeutics Inc. stock bottoming outQuarterly Trade Summary & Community Consensus Trade Signals - newser.com
Why Candel Therapeutics Inc. stock remains undervalued2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Candel Therapeutics to present insights from enLIGHTEN Discovery Platform at SITC 2025 meeting - Proactive financial news
Candel Therapeutics to Present at the SITC 2025 Annual Meeting - The Manila Times
Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting - Quiver Quantitative
Is Candel Therapeutics Inc. stock a smart buy before Fed meetingMarket Growth Summary & Stock Portfolio Risk Control - newser.com
Using Ichimoku Cloud for Candel Therapeutics Inc. technicals2025 Buyback Activity & Precise Buy Zone Tips - newser.com
Positive Phase 3 CAN-2409 data — Candel Therapeutics presents prostate cancer & NSCLC at SITC Nov 2025 - Stock Titan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):